a. Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair. Olszewska-Pazdrak B, McVicar SD, Rayavara K, Moya SM, Kantara C, Gammarano C, Olszewska P, Fuller GM, Sower LE, Carney DH. Radiat Res. 2016 Aug;186(2):162-74. doi: 10.1667/RR14409.1. Epub 2016 Jul 7.PMID: 27388041 https://pubmed.ncbi.nlm.nih.gov/27388041/
b. Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity. Kantara C, Moya SM, Houchen CW, Umar S, Ullrich RL, Singh P, Carney DH. Lab Invest. 2015 Nov;95(11):1222-33. doi: 10.1038/labinvest.2015.103. Epub 2015 Aug 17.PMID: 26280221 https://pubmed.ncbi.nlm.nih.gov/26280221/
c. Radiomitigation and Tissue Repair Activity of Systemically Administered Therapeutic Peptide TP508 Is Enhanced by PEGylation. McVicar SD, Rayavara K, Carney DH. AAPS J. 2017 May;19(3):743-753. doi: 10.1208/s12248-016-0043-7. Epub 2017 Jan 17.PMID: 28097629 https://pubmed.ncbi.nlm.nih.gov/28097629/
The TP508 Solution for Nuclear Radiation Exposure
Mitigation of Radiation-Induced Vascular Damage
About Us
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.
Let’s Socialize
Popular Post
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics today announced it was selected to participate in the
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug
Galveston firm to test potential ‘game-changer’ in lung disease treatment
GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance